ASH Annual Meeting 2022 – Research and insight summary

ASH Annual Meeting 2022 - summary and key take-outs By Dr Zoe Drymoussi During the 9-12th December 2022, the FLF team attended, in person, for the biggest events of the year in the world of haematology – the American Society of Hematology (ASH) annual meeting. More...

Looking back over the last 25 years for FL – the Rituximab era

Looking back over the last 25 years for FL – the Rituximab era By Dr Mitchell Smith, Chief Medical Officer A recent re-publication marking 25 years since the seminal 1998 Journal of Clinical Oncology paper (1) upon which Rituximab was approved for relapsed/refractory...

The FLF’s Precision Medicine Programme research goals

The FLF’s Precision Medicine Programme Research Goals Technical abstract: The FLF undertook extensive landscaping and scoping work, identifying a substantial set of unmet needs in follicular lymphoma that the Precision Medicine Programme (PMP) could help to address....

Research in focus: Bi-specific antibodies approval.

Research in focus: Bi-specific antibodies approval. By Dr. Zoe Drymoussi Over the last few years, a promising new class of treatments for advanced-stage FL has been in development, with mosunetuzumab being the first in this class to be approved in Europe (by the EMA;...

FLF are attending the ASH 2022 Annual Meeting

FLF are attending the ASH 2022 Annual Meeting We are delighted that some of the team are able to attend the 64th ASH Annual Meeting and Exposition, in New Orleans Louisiana, USA from the 10th to the 13th December 2022.The FLF team will be attending sessions, building...